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INTRODUCTION
The two types of human light chains, and , are found among all classes of immunoglobulin (Ig) molecules and are characterized by a common structure consisting of ϳ107 amino-terminal amino acid residues, which is the variable (V) region, and ϳ107 carboxyl-terminal residues, which is the constant (C) region. The light-chain V region (V L ) is specified by two gene segments, V and J, that encode the first 95 to 98 amino acids and the following 12 () or 13 () joining (J)-region residues, respectively. The light-chain C region (C L ) is encoded by a third gene, C. Despite their structural similarity, and light chains are the products of genes that differ profoundly in location, number, and organization. The human -light-chain locus, found on chromosome 2, contains multiple V genes, five tandemly arranged J-gene segments, and one C gene. The human -light-chain locus, situated on chromosome 22, also contains multiple V genes but differs from in the number of C genes (at least seven, of which four are functional) and by the association of each with a particular Jencoding segment. Notably, -light-chain-gene recombination occurs only after failure of either allele to rearrange productively. The extensive diversity in human light-chain V-region sequences reflects primarily the number of functional V or V genes (ϳ40 each), as well as substitutions caused by somatic mutation. Additional diversity results from the combinatorial joining of V-and J-gene segments and the variation introduced at the site of V-J recombination, including the insertion of extra bases (P or N nucleotides).
The elucidation of human light-chain-related genes and their regulatory factors is fundamentally important to understanding B-cell development as well as antibody structure and function. Especially relevant is the pathogenic relationship between light-chain-gene expression and neoplastic and autoimmune disease. Compared with , considerably less information is available on , particularly in regard to the structural features of V genes. However, light chains are biologically important, as evidenced by the fact that they are found on ϳ30 to 40% of human Ig molecules in the normal state and to an even greater extent in individuals with certain malignant and inflammatory disorders. The purpose of this minireview is to summarize the existing knowledge on the human V locus and to elucidate the biologic, chemical, and functional properties of its protein products as well as their clinical relevance.
HUMAN V GENES
Sequence and immunochemical analyses of Bence Jones proteins and light chains isolated from monoclonal Igs have provided considerable insight into the structural diversity of human light chains. Notably, the V L contains three regions of extensive sequence variability termed the hypervariable or complementarity-determining regions (CDRs); these areas are involved in the antigen-binding and idiotype sites. The remaining portions of the V L consist of four regions of lesser sequence variability that provide a structural framework for the CDRs and are thus designated the framework regions (FRs). Homologies in sequence, especially in FR1, initially provided the chemical basis for classification of (and ) light chains into multiple subgroups (28) . These V L subgroups are isotypic in nature; i.e., molecules representative of each are found among Ig light chains in normal serum (2) . Five of the six V subgroups (V I , V II , V III , V IV , and V VI ) were recognized by polyclonal and monoclonal anti-light-chain reagents (1, 40) . However, in the case of the sixth subgroup, V V , those proteins originally designated as members of this subgroup reacted exclusively with anti-V II -specific reagents and were thus reclassified as II (1, 40) . Subsequently, at the molecular level, the genes encoding the five V subgroups were identified (3, 4, 7, 9, 12, 14-17, 22-24, 27, 38, 46, 49, 51) , and Southern blotting data confirmed that the V V and V II subgroups were indistinguishable (15) .
Through isolation and amplification of cDNA libraries derived from monoclonal B-cell populations of RNA and cloning and sequencing of genomic DNA with subgroup-specific primers, seven additional V -gene families have since been recognized. They were termed V VII (5, 14) , V VIII (11, 18, 36, 42) , V IX (18, 49) , V X (43), T1 (6), V N.2 (15) , and V8/DPL21 (49, 50) . Furthermore, the multigene nature of certain V -gene families (particularly V I , V II , and V III ) has been evidenced by Southern blotting under conditions of high stringency. These V subgroups have been divided into sub-subgroups on the basis of sequence and/or serologic similarities (14-17, 19, 21, 22, 24, 27, 40, 44, 49) .
Thus, among the ϳ70 genes that make up the human V locus (5) (of which about one-half are potentially functional [17, 49] ), it is probable that virtually all of the V -gene families have been identified. Although the criteria as to what constitutes a distinct family or subgroup have not been firmly established, traditionally, this differentiation has been made on the basis of a Ͼ90 or Ͼ80% sequence homology at the nucleotide or protein level, respectively. Sub-subgroups display an even higher degree of identity among family members.
The prototypic nucleotide and translated protein sequences of the functional human V germline genes encoding the 12 presently characterized V subgroups (and sub-subgroups) are given in Fig. 1 .
V -gene-family nomenclature. As stated above, the classification of V genes and their expressed products into distinct subgroups or families (designated by Roman numerals) has been based on sequence homologies and serologic analyses.
Unfortunately, considerable confusion concerning nomenclature has been generated because of misclassification (23, 28, 29) , arbitrary reassignment of newly recognized V subgroups into previously defined categories (14) , and use of previously termed V subgroup numbers for completely different V -gene families (14, 50) . A summary of published V -subgroup or -gene-family designations, as well as our proposed nomenclature system, is given in Table 1 . A listing of the V I , V II , and FIG. 1. Nucleotide and deduced amino acid sequences of prototypic germline genes encoding human V subgroups and sub-subgroups. The numbering system used is that of Kabat et al. (28) . The presence of additional FR and CDR residues is indicated by lowercase letters. V III sub-subgroups and their corresponding germline genes are provided in Table 2 . For purposes of consistency in naming V subgroups, we recommend that any newly recognized Vgene families or sub-subgroups be indicated by consecutive Roman numerals or letters, respectively, on the basis of the order of discovery as determined by publication date. Final terminology will ultimately depend on elucidation of the entire human V locus. Organization of human V genes. In contrast to the extensive molecular characterization of the human V locus (for a review, see reference 52), similar information on V has only recently become available. Studies to date indicate that V VI , V X , and V I genes are most distant from the J -C complexes, while V III and V II are closest in proximity (15, 24, 43) . The positions of these gene families along the chromosome and that of the J C segments are schematically indicated in Fig. 2 . It should be noted that (as for V ) these V -gene families are not necessarily segregated but can be interspersed; e.g., while the majority of V I and V II genes have been mapped to the 5Ј and 3Ј portions of the V locus, respectively, members of both gene families have been identified in opposite locations.
Although sequence variations have been noted in the Vassociated promoter, TATA box, and leader exons (12, 24, 43, 46, 49) , subgroup-related differences have not as yet been found. All V exons have an identical nonamer and heptamer recombination signal sequence and can combine with any of the four functional J genes (43, 45) . Furthermore, as in the case of genes, V -J recombination results from a deletion mechanism (15, 24) .
Structural characteristics of human V subgroups. The human V subgroups are distinguished not only by amino acid sequence homologies but also by the presence of characteristic numbers of residues within CDRs as well as FRs. As indicated in Table 3 , these differences are most evident in CDR1 (11 to 14 residues), CDR2 (7 to 12 residues), and CDR3 (7 to 11 residues). The number of CDR3 residues reflects not only V exon nucleotide composition but also the variation resulting from V-J recombinational events and the introduction of P or N nucleotides (30, 47) . In FR1, certain III light chains contain 21, rather than 22, residues, and VI and XI (T1) components are characterized by two additional FR3 residues. Although data on the tertiary structural features of light chains are limited, it would be expected that the compositional differences found among the V subgroups, particularly those in the CDRs, would significantly affect the nature of the antigenbinding site (13) .
Expression of human V genes in normal and disease states. The light-chain products of the Ͼ40 functional human V genes identified to date have been found among monoclonal serum and urinary -type Igs and/or sIg ϩ B-cell populations. That these V -gene products are expressed in the normal state has been evidenced through serologic analyses of serum and lymphocytes taken from healthy individuals. We have used our monoclonal antibodies specific for I, II, III (IIIa, IIIb, (15, 24, 43, 45) . Distance within the V region is not to scale; the 3Ј enhancer (E) is 11.7 kb 3Ј of C 7 (the figure was modified from reference 8). n, tentative location of other human V -gene families. IIIc), IV, VI, and VIII light chains (1, 2, 34) to determine the concentrations and relative distributions of these particular subgroups and sub-subgroups among polyclonal -type Ig molecules contained in the serum of healthy adults (Table 4) . Summation of the relative concentration of each of these six V subgroups was comparable to that of total chains as determined with an anti-C reagent. This finding would indicate that the IX, X, XI (T1), XII (V N.2), and XIII (V8/DPL21) subgroups (for which there are as yet no available antibodies) represent Ͻ1% of the total -light-chain population. Additionally, the V -subgroup distribution among sIg ϩ B-cell populations in healthy adults was comparable to that of polyclonal serum -type Igs (42a).
In contrast to the healthy state, in which IgI, IgII, IgIII, IgIV, IgVI, and IgVIII molecules represent ϳ40, 3, 43, 5, 5, and 3%, respectively, of the total Ig population, certain V -gene families are preferentially expressed in individuals with monoclonal plasma cell-and B-cell-related neoplastic or immunoproliferative disorders (34) ( Table 5 ). Serologic analyses of -type IgG, IgA, and IgD myeloma proteins and Bence Jones proteins obtained from 196 patients with multiple myeloma and related gammopathies and 41 patients with lightchain-associated (AL) amyloidosis revealed approximately nine-and sevenfold higher percentages of II components, respectively; among 16 Waldenström's macroglobulins, twothirds were classified as IgMII. The functional importance of this V subgroup has been evidenced by its association with certain autoimmune and antibacterial antibodies; e.g., the V II -gene family encodes exclusively for the -light-chain-related 8.12 idiotype present on one-third of anti-DNA antibodies found in the sera of patients with systemic lupus erythematosus (35) .
Our analyses of associated Igs confirmed that the V VI subgroup is preferentially associated with this form of amyloidosis (39); 17 of 41 amyloid-associated proteins were classified as IgVI. To date, we have found no V VI -related components among -type myeloma proteins, Waldenström's macroglobulins, IgM rheumatoid factors, or sIg ϩ chronic lymphocytic leukemia cell populations (34, 41) . c Monoclonal IgM rheumatoid factors (RFs) produced by 27 immortalized peripheral blood or synovial B cells from patients with rheumatoid arthritis (11, 20, 34a) .
Other examples of the skewed distribution of V subgroups include monoclonal IgM rheumatoid factors produced by Epstein-Barr virus-immortalized cell lines prepared from peripheral blood or synovial B cells from patients with rheumatoid arthritis (22, 36) (Table 5) . In these cases, we have found that the percentages of the relatively uncommon V IV and V VIII subgroups were increased approximately four-and sixfold, respectively, above normal (20, 42) . Additionally, a predominance of IIIb-containing proteins was evidenced among IgM rheumatoid factors having specificity for rabbit IgG (19, 22) . An apparently biased expression of the V IV subgroup with other types of autoantibodies has also been demonstrated, e.g., among anti-D(Rh) (10), antilysozyme (33) , antithyroglobulin (26) , and antisperm antibodies (51), as well as in sIg ϩ chronic lymphocytic leukemia cell populations (41) . The VII nature of vaccine-induced anti-Haemophilus influenzae type b polysaccharide antibodies bearing the cross-reactive idiotype HibId-2 (25) and the association of IX and XIII (V8/DPL21) light chains with other types of autoantibodies have also been reported (32, 49, 50) . Additionally, a preferential usage of I light chains was noted among anti-gp120 antibodies in the sera of human immunodeficiency virus type 1-infected individuals (48) .
The molecular basis for the nonstochastic expression of V subgroups in patients with neoplastic and inflammatory diseases is unknown. Whether the use of specific V -gene families in these disorders reflects (i) the propensity of particular B cells to undergo Epstein-Barr virus-induced transformation, (ii) a unique antibody response, (iii) chromosomal location (i.e., the proximity to J C segments), or (iv) alterations in transcriptional regulation remains to be established. Alternatively, the apparent overexpression of particular V genes may be related to their possible overrepresentation in the fetal repertoire, as has been found for certain V H -gene families (37) .
